|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2005-2-25
|
|
pubmed:abstractText |
We and others have shown that B cell precursor acute lymphoblastic leukemia cells (ALL) stimulated with CD40 ligand become efficient antigen-presenting cells (APC) capable of expanding autologous, tumor-specific T cells from patients. Translation of these preclinical findings to a novel treatment strategy required four separate issues to be determined: (1) if a CD40-ALL vaccine could be generated for clinical use; (2) whether clinical translation could be achieved; (3) whether the vaccination was safe; and (4) whether a window of time could be identified that would optimize the efficacy of vaccination.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0301-472X
|
|
pubmed:author |
pubmed-author:CardosoAngelo AAA,
pubmed-author:DeAngeloDaniel JDJ,
pubmed-author:FlemingMarkM,
pubmed-author:GalinskyIleneI,
pubmed-author:GuinanEva CEC,
pubmed-author:HainingW NicholasWN,
pubmed-author:KeczkemethyHeather LHL,
pubmed-author:NadlerLee MLM,
pubmed-author:NeubergDonnaD,
pubmed-author:SallanStephen ESE,
pubmed-author:SilvermanLewis BLB,
pubmed-author:StoneRichard MRM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
33
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
286-94
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15730852-Adolescent,
pubmed-meshheading:15730852-Adult,
pubmed-meshheading:15730852-Antigen-Presenting Cells,
pubmed-meshheading:15730852-Antigens, CD40,
pubmed-meshheading:15730852-Cancer Vaccines,
pubmed-meshheading:15730852-Child,
pubmed-meshheading:15730852-Child, Preschool,
pubmed-meshheading:15730852-Female,
pubmed-meshheading:15730852-Humans,
pubmed-meshheading:15730852-Immunotherapy, Adoptive,
pubmed-meshheading:15730852-Male,
pubmed-meshheading:15730852-Middle Aged,
pubmed-meshheading:15730852-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:15730852-Recurrence,
pubmed-meshheading:15730852-T-Lymphocytes,
pubmed-meshheading:15730852-Time Factors
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia.
|
|
pubmed:affiliation |
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. nicholas_haining@dfci.harvard.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
